healthday on MSN10d
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...
Cure Today6d
Braftovi Plus Erbitux With mFOLFOX6 May Improve Responses in BRAF V600E+ mCRC
Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...
Armed robbery in Revesby10d
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
Benzinga.com11d
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...
Nasdaq11d
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
“The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look ...
PMLiVE10d
Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer
Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...